Furthermore, a phase II clinical trial of novel SLP vaccines for melanoma (NCT00118274) demonstrated a significant enhancement in overall survival (OS) when administered alongside the adjuvant 12MP (targeting CD8 + T cells) and 6MHP (targeting CD4 + T cells) in patients with stage IIB to IV melanoma, with long-term DFS seen in patients with partially recurrent resectable disease [53]. Here, CD4 is linked to melanoma.